FDA Approves Voceryq to Treat Recurrent Respiratory Papillomatosis

The United States Food and Drug Administration granted accelerated approval on October 30, 2026, to Voceryq, marking the first plasmid DNA-based immunotherapy authorized in the United States for adults with recurrent respiratory papillomatosis.

Key Clinical Takeaways:

• Voceryq received accelerated approval from the FDA on October 30, 2026, for recurrent respiratory papillomatosis.
• The therapy utilizes two plasmid DNA rings and electrical pulses to target HPV 6 and 11 infected cells.
• Initial clinical data showed a 27% complete response rate among patients who previously required frequent surgical interventions.

Regulatory Status and Clinical Limitations of Voceryq

The regulatory milestone advances the treatment of recurrent respiratory papillomatosis, a rare condition driven primarily by human papillomavirus types 6 and 11. The approval is accelerated and derives from an uncontrolled trial involving 32 participants, meaning definitive proof of efficacy requires confirmation through a new clinical trial. The treatment is not yet authorized in Europe.

Viral Pathogenesis and Surgical Burden

Recurrent respiratory papillomatosis causes benign growths to form predominantly on the larynx and vocal cords, triggering hoarseness, voice loss, cough, and severe airway obstruction. Surgical removal clears the airway but fails to eliminate the underlying tissue infection. Patients often endure repeated operations over many years under general anesthesia, carrying a progressive risk of permanent vocal cord scarring. Literature reviews indicate that individuals with severe disease courses undergo dozens of lifetime procedures.

Mechanism of Action and Delivery Protocol

Voceryq, scientifically designated as doruxapapogene ralaplasmid and lalikinogene sifuplasmid, alters the therapeutic approach by targeting the viral infection rather than excising the tissue physically. The product introduces two plasmid DNA rings following surgical debulking. The first ring encodes specific viral proteins from HPV 6 and 11, while the second encodes interleukin-12, a molecule designed to bolster immune response. Administration occurs via intramuscular injection every three weeks for a total of four doses. A dedicated device then applies brief electrical pulses to open temporary pores in cellular membranes, facilitating plasmid entry. Consequently, the treatment requires specialized personnel and electroporation equipment rather than standard outpatient injection.

Treatment Reduces Yearly Procedures Despite Common Side Effects

The FDA approval rests on data showing that out of 26 patients who underwent at least three operations in the preceding twelve months, seven required no further surgical interventions during the following year. An observational extension demonstrated that the mean number of yearly procedures dropped from 4.1 before therapy to 1.7 in the first year and 0.9 in the second year. However, these open-label findings lack a control group and do not prove viral eradication. Common adverse events include injection site reactions, headache, fatigue, elevated blood pressure, nausea, and dizziness. Electroporation can also induce brief muscle contractions, pain, or vasovagal responses.

FDA Mandates Confirmatory Trial for Therapeutic Benefits

The FDA mandates a confirmatory trial to establish whether therapeutic benefits persist, which patient subgroups respond best, and to quantify reductions in surgical frequency and voice complications. Preventive HPV vaccination remains essential for reducing circulation of the virus. Integration into standard clinical practice within the National Health Service awaits European authorization, evaluation by the Italian Medicines Agency, and the establishment of equipped otolaryngology centers.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.